IMMUNOTHERAPY FOR HER2 POSITIVE BREAST CANCER

被引：0
|
作者：
Vaidya, T. R. [1 ]
Ait-Oudhia, S. [1 ]
机构：
[1] Univ Florida, Coll Pharm, Orlando, FL USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 101卷 / S1期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PI-003
引用
收藏
页码：S20 / S20
页数：1
相关论文
共 50 条
  • [41] Identifying efficacy of targeted HER2 antibodies in sensitization of HER2 positive breast cancer to fractionated radiation
    Song, Patrick N.
    Lu, Yun
    Napier, Tiara
    Samuel, Sharon
    Heinzman, Katherine
    Lapi, Suzanne E.
    Sorace, Anna G.
    CANCER RESEARCH, 2021, 81 (04)
  • [42] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Zhang, Chao
    Suo, Aili
    Shi, Qiuying
    Wei, Zhimin
    Li, Zaibo
    Krishnamurti, Uma
    Li, Xiaoxian
    MODERN PATHOLOGY, 2019, 32
  • [43] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Kaur, Sumanpreet
    Bhattacharyya, Rajasri
    Banerjee, Dibyajyoti
    Shukla, Jaya
    INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY, 2021, 36 (01) : 124 - 125
  • [44] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Zhang, Chao
    Suo, Aili
    Shi, Qiuying
    Wei, Zhimin
    Li, Zaibo
    Krishnamurti, Uma
    Li, Xiaoxian
    LABORATORY INVESTIGATION, 2019, 99
  • [45] Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
    Stanowicka-Grada, Malwina
    Senkus, Elzbieta
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (11) : 1633 - 1650
  • [46] Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer
    Guarneri, V.
    Barbieri, E.
    Dieci, M. V.
    Piacentini, F.
    Conte, P.
    CANCER TREATMENT REVIEWS, 2010, 36 : S62 - S66
  • [47] HER2 mutation status in Japanese HER2-positive breast cancer patients
    Yumi Endo
    Yu Dong
    Naoto Kondo
    Nobuyasu Yoshimoto
    Tomoko Asano
    Yukari Hato
    Mayumi Nishimoto
    Hiroyuki Kato
    Satoru Takahashi
    Ryoichi Nakanishi
    Tatsuya Toyama
    Breast Cancer, 2016, 23 : 902 - 907
  • [48] HER2 mutation status in Japanese HER2-positive breast cancer patients
    Endo, Yumi
    Dong, Yu
    Kondo, Naoto
    Yoshimoto, Nobuyasu
    Asano, Tomoko
    Hato, Yukari
    Nishimoto, Mayumi
    Kato, Hiroyuki
    Takahashi, Satoru
    Nakanishi, Ryoichi
    Toyama, Tatsuya
    BREAST CANCER, 2016, 23 (06) : 902 - 907
  • [49] HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
    Hosonaga, Mari
    Arima, Yoshimi
    Sampetrean, Oltea
    Komura, Daisuke
    Koya, Ikuko
    Sasaki, Takashi
    Sato, Eiichi
    Okano, Hideyuki
    Kudoh, Jun
    Ishikawa, Shumpei
    Saya, Hideyuki
    Ishikawa, Takashi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (08)
  • [50] Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
    Malwina Stanowicka-Grada
    Elżbieta Senkus
    Current Treatment Options in Oncology, 2023, 24 : 1633 - 1650
12345